MissionIR Articles
-
MissionIRNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Driving Clean Energy Innovation Through Multiple Projects
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S. The company recently announced a partnership with Viridi, the industry leader in fail-safe battery energy storage systems (“BESS”),…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Highlights U.S. Assembly and Tariff Exempt Status for EV Lineup
Mullen Automotive (NASDAQ: MULN) announced that its Mullen and Bollinger commercial electric vehicles are fully assembled in the United States and exempt from recently announced tariffs on vehicles and components. With 67% and 71% of components sourced domestically for Mullen and Bollinger respectively, the company emphasizes its commitment to U.S. manufacturing and supply chain stability.…
-
MissionIRNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Surpasses 800 Advertisers, Maintains 243% CAGR Amid Rapid Expansion
Thumzup (NASDAQ: TZUP), a rising AdTech player in social media branding and programmatic marketing, announced it has exceeded 800 advertisers on its platform, with expectations to cross 1,000 by mid Q2 2025. The company reported a 243% compound annual growth rate, fueled by strategic expansion into South Florida, Miami, and Greater Salt Lake City. Thumzup’s…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position
CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D spending. Despite Berubicin missing its primary endpoint in a glioblastoma multiforme (GBM) trial, the drug demonstrated safety and comparable efficacy, guiding future analysis. The…
-
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference on April 9
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases like ALS and MS, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, at 11:30 a.m. PT. The event will be held at the Venetian Resort in Las Vegas and include 1×1 investor meetings. A webcast of the…
-
MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, closed its previously announced registered direct offering and concurrent private placement with a single institutional investor, raising approximately $3.9 million in gross proceeds. The offering included 3,325,000 shares of common stock and pre-funded warrants for 2,728,000 shares, along with Series G warrants for…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Defeats Motion to Dismiss in Spoofing Lawsuit
Mullen Automotive (NASDAQ: MULN), an electric vehicle manufacturer, announced a key legal victory after a federal court denied a motion to dismiss its spoofing lawsuit against IMC Financial Markets, Clear Street Markets LLC, UBS Securities LLC, and others. The lawsuit alleges that defendants used high-frequency algorithmic trading tactics—including “Baiting Orders”—to manipulate Mullen’s stock price between…
-
MissionIRNewsBreaks – GivBux Inc. (OTC: GBUX) Plans $212 Million Equity Sale Through Non-Dilutive Structure
GivBux (OTC: GBUX), a publicly traded Super App and charitable giving platform, announced plans to sell a 30% equity stake for $212 million through a non-dilutive transaction aimed at preserving shareholder value. Proceeds will be invested in an income-focused strategy led by a private credit asset manager specializing in real estate, with the goal of…
-
MissionIRNewsBreaks – Powered by Physics: Newton Golf Company’s (NASDAQ: NWTG) Rebrand Spotlights Game-Changing Technology
Newton Golf (NASDAQ: NWTG) has completed a strategic rebranding to emphasize its commitment to innovation and align more closely with its mission of integrating advanced physics principles into golf-equipment design. The restructuring was not merely a change in name but a reflection of Newton Golf’s dedication to creating equipment that leverages the laws of physics to…
-
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell
Scinai Immunotherapeutics (NASDAQ: SCNI), announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing PC111, a first-in-class antibody targeting severe skin blistering disorders. In tandem, Scinai’s Polish subsidiary submitted a €12 million non-dilutive grant application under the EU’s FENG program to fund the next development phase of PC111. The…
-
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Las Vegas Technology and Innovation Conference
Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases such as ALS and MS, will participate in the Jones Las Vegas Technology and Innovation Conference on April 8–9, 2025. Held at The Venetian Resort, the event will feature one-on-one meetings, panels, and networking with institutional investors. Clene CEO Rob Etherington will represent the…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, has selected IBN to manage its corporate communications and investor outreach. Soligenix is advancing late-stage clinical programs through its oncology and inflammation-focused Specialized BioTherapeutics segment and its Public Health Solutions division, which develops vaccines for biothreats such as ricin, Ebola, and Marburg. With support from…
-
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), is actively advancing its lead drug candidate, CNM-Au8®. The company presented its progress at two key investor events…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced its recent accomplishments and financial results for the year ended Dec. 31, 2024. “We remain highly focused on advancing our multiple clinical programs as we work towards achieving a…
-
MissionIRNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Fuels Explosive Growth with Disruptive AdTech Platform
Thumzup (NASDAQ: TZUP) is leveraging its proprietary social media marketing platform, AdTech, which drives influencers to catapult the effectiveness of small-business advertising. Having achieved a growth rate of over 200% CAGR, Thumzup now serves more than 700 clients, with projections to exceed 1,000 by the next financial quarter. As social media marketing continues to grow, Thumzup’s…
-
MissionIRNewsBreaks – Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. “Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases,” reads a…
-
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Present at BIO-Europe Spring 2025
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and contract development and manufacturing (CDMO) services, announced its participation in the BIO-Europe Spring 2025 conference from March 17-19 in Milan, Italy. The company’s leadership will meet with potential pharmaceutical partners, prospective CDMO clients, and institutional investors to showcase its…
-
MissionIRNewsBreaks – D-Wave Reports Fourth Quarter and Year-End 2024 Results
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has announced its financial results for fourth quarter and year-end 2024, with a 128% year-over-year increase in bookings, reaching $23.9 million in bookings for the year ended December 31, 2024. The company also announced a consolidated cash balance that now…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Appoints Kasowitz LLP to Strengthen Intellectual Property and Litigation Capabilities
- MissionIRNewsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Secures First DefendAir CUAS Order from Israeli Defense Entity
- MissionIRNewsBreaks – Rail Vision Ltd. (NASDAQ: RVSN) to Be Showcased at CES 2026 Through Israel Railways Partnership
- MissionIRNewsBreaks – A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) Announces Board Leadership Transition
- GlobalTech Corporation (GLTK) Advances Global Retail Expansion Through Planned Moda in Pelle Acquisition, Supporting AI-Driven Growth Strategy